Savara is an orphan lung disease company.
Savara’s primary focus is IMPALA 2, a second Phase 3 clinical study of Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The company is also conducting another pivotal Phase 3 study, called AVAIL, that is evaluating AeroVanc for the treatment of MRSA in people living with cystic fibrosis.
We focus on rare respiratory diseases in order to give patients with unmet medical needs better treatment options.
Visit our PAP portal where patients and doctors can learn more about this disease
Savara Nasdaq Opening Bell Ceremony - July 23, 2018×